

Table 1. Clinicopathologic features and p53 co-expression measurements for primary *NPM1*-AML tissue samples.

Study #	M/F	Age	WBC	Hb	Plt	BM Blast %	PB Blast %	Karyotype	NPM1 VAF	p53+ of NPM1c+	Co-Mutations (Tiers I & II)	FLT3 -ITD	Induction	CR/CRi/PD
NPM1c-1	F	37	1.2	8.0	52.0	25	0.0	NK	N/A	0.30	N/A	N	7+3	CR
NPM1c-2	M	60	73.0	11.3	103.0	84	65.0	47,XY,+8[1]/46,XY[19]	N/A	0.81	N/A	N/A	7+3	CRi
NPM1c-3	F	65	2.9	9.3	81.0	51	1.0	NK	N/A	0.12	<i>DNMT3A</i> , <i>TET2</i>	N	7+3	CR
NPM1c-4	M	64	30.8	10.1	94.0	24	43.0	46,XY,inv(9)(p12q13)c[20]	N/A	0.09	None	Y	7+3	PD
NPM1c-5	M	26	89.9	9.8	13.0	69	69.0	NK	N/A	0.11	<i>DNMT3A</i> , <i>FLT3</i> -TKD	N	7+3	CR
NPM1c-6	F	37	44.0	6.6	56.0	85	97.0	NK	N/A	0.43	<i>IDH1</i> , <i>FLT3</i> -TKD	N	7+3	CR
NPM1c-7	F	50	17.4	10.3	50.0	89	59.0	NK	0.560	0.13	None	Y	7+3	CR
NPM1c-8	F	74	44.0	8.8	27.0	96	92.0	NK	0.440	0.17	<i>DNMT3A</i> , <i>TET2</i>	Y	N/A	N/A
NPM1c-9	F	56	23.3	9.5	71.0	86	90.0	NK	0.460	0.38	<i>IDH1</i>	Y	7+3	CR
NPM1c-10	F	94	N/A	N/A	N/A	53	4.0	NK	0.280	0.11	<i>DNMT3A</i> , <i>TET2</i> , <i>SF3B1</i>	Y	Decitabine	PD
NPM1c-11	F	73	18.0	8.3	92.0	75	7.0	NK	0.400	0.06	<i>DNMT3A</i> , <i>TET2</i>	N	LDAC/Ven	PD
NPM1c-12	M	63	74.3	7.8	36.0	88	90.0	NK	0.510	0.13	<i>DNMT3A</i> , <i>PTPN11</i> , <i>NF1</i>	N	N/A	N/A
NPM1c-13	M	51	39.8	7.3	42.0	53	29.0	NK	0.500	0.24	<i>DNMT3A</i> , <i>NRAS</i>	Y	7+3	CR
NPM1c-14	F	45	16.0	7.5	361.0	65	14.0	NK	0.420	0.07	<i>DNMT3A</i> , <i>CEBPA</i>	N	7+3	CR
NPM1c-15	F	42	73.2	10.1	64.0	90	80.0	NK	0.460	0.49	<i>DNMT3A</i>	Y	7+3 plus midostaurin	CR
NPM1c-16	M	85	9.6	8.7	45.0	88	89.0	NK	0.360	0.06	<i>DNMT3A</i> , <i>IDH1</i>	N	N/A	N/A
NPM1c-17	M	62	75.5	12.4	40.0	86	80.0	47,XY,+8[13]/46,XY[2]	0.450	0.55	<i>DNMT3A</i> , <i>ASXL1</i> , <i>FLT3</i> -TKD	N	7+3	CR
NPM1c-18	F	56	22.6	9.9	23.0	93	94.0	NK	0.640	0.43	<i>DNMT3A</i> , <i>TET2</i>	Y	7+3	CR
NPM1c-19	M	56	6.8	7.9	72.0	83	71.0	NK	0.470	0.22	<i>DNMT3A</i> , <i>IDH2</i> , <i>ZRSR2</i>	N	7+3	CR
NPM1c-20	M	67	120.3	8.6	22.0	98	98.0	NK	0.540	0.20	<i>IDH2</i> , <i>SRSF2</i> , <i>FLT3</i> -TKD	N	N/A	N/A
NPM1c-21	F	70	27.0	10.9	122.0	44	50.0	NK	0.370	0.14	<i>DNMT3A</i> , <i>IDH1</i>	N	Decitabine	PD
NPM1c-22	M	72	1.0	9.2	28.0	73	5.0	48,XY,+8,+8[20]	0.170	0.45	<i>DNMT3A</i> , <i>NF1</i> , <i>NRAS</i>	N	CPX-351	CR
NPM1c-23	F	58	313.8	8.5	36.0	97	95.0	NK	0.580	0.36	<i>TET2</i> , <i>FLT3</i> -TKD	N	N/A	N/A
NPM1c-24	F	61	2.8	11.5	122.0	88	65.0	NK	0.430	0.15	<i>DNMT3A</i> , <i>IDH1</i>	N	CPX-351	CR
NPM1c-25	M	69	21.0	10.5	123.0	70	2.0	NK	0.340	0.27	<i>TET2</i> , <i>PTPN11</i> , <i>IDH1</i>	N	N/A	N/A
NPM1c-26	F	77	90.5	6.3	33.0	70	82.0	NK	0.440	0.27	None	Y	Aza/Ven	CRi
NPM1c-27	F	57	1.1	8.5	42.0	70	27.0	NK	0.190	0.07	<i>IDH1</i>	N	7+3	CR
NPM1c-28	M	58	12.4	6.5	25.0	33	9.0	45,X,-Y[11]/46,XY[9]	0.460	0.03	<i>DNMT3A</i>	N	7+3	PD
NPM1c-29	F	58	14.2	11.1	30.0	30	45.0	NK	0.399	0.12	<i>NRAS</i> , <i>IDH2</i>	N	7+3	CR
NPM1c-30	M	47	46.0	8.1	17.0	75	57.0	NK	0.405	0.05	<i>DNMT3A</i> , <i>FLT3</i> -TKD	Y	7+3	CR (IHC/PCR+)
NPM1c-31	F	30	3.9	7.3	94.0	70	20.0	NK	0.282	0.16	<i>DNMT3A</i> , <i>CEBPA</i> , <i>ETV6</i> ,	N	N/A	CR (IHC/NGS MRD+)
NPM1c-32	M	53	67.3	11.1	70.0	75	48.0	NK	0.427	0.08	<i>TET2</i> , <i>WT1</i>	N	PALG trial	PD
NPM1c-33	M	66	1.6	12.9	170.0	57	3.0	NK	0.205	0.02	<i>NRAS</i> , <i>IDH1</i> , <i>WT1</i>	N	N/A	CRi (IHC/PCR MRD+)

WBC, white blood cell count (k/uL); Hb, hemoglobin concentration (g/dL); Plt, platelet count (K/uL); BM, bone marrow; PB, peripheral blood; NK, normal karyotype; VAF, variant allele frequency; NPM1c, mutant NPM1, CR, completion remission; CRi, complete remission with incomplete count recovery; PD, persistent disease (i.e. BM blast >5%); LDAC, low-dose cytarabine; Aza, azacitidine; Ven, venetoclax; PALG, daunorubicin/cytarabine +/- cladribine; IHC; immunohistochemistry NGS; next generation sequencing; PCR; polymerase chain reaction; MRD; minimal/measurable residual disease